Results 21 to 30 of about 2,022,996 (246)

tianshilu/QBRC-Neoantigen-Pipeline: First release

, 2021
QBRC Neoantigen calling pipeline with CSiN calculation ...
Neoantigen-pipeline, tianshilu
core   +1 more source

Targeting tumor heterogeneity with neoantigen-based cancer vaccines

, 2023
Neoantigen-based cancer vaccines have emerged as a promising immunotherapeutic approach to treat cancer. Nevertheless, the high degree of heterogeneity in tumors poses a significant hurdle for developing a vaccine that targets the therapeutically ...
Chen, Shuxiong, Ma, Linlin, Pounraj, Saranya, Mazzieri, Roberta, Rehm, Bernd HA, Dolcetti, Riccardo   +5 more
core   +1 more source

Supplementary Data from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

, 2021
Supplementary Data from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance ...
Pamela Milani (470521), Rachel Marty Pyke (15033824), Michael P. Snyder (15033839), Eric Levy (3713023), Dattatreya Mellacheruvu (531667), Sekwon Jang (8899451), Fábio C.P. Navarro (15033827), Mengyao Tan (14933070), Richard Chen (819249), Simo V. Zhang (6103124), Jason Harris (60019), Charles W. Abbott (9402235), Gabor Bartha (3549785), Lee D. McDaniel (4033088), Rose Santiago (15033830), Sean M. Boyle (15033821), Zeid M. Rusan (15033833), Rena McClory (15033836)   +17 more
core   +2 more sources

Supplementary Figure from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

, 2021
Supplementary Figure from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance ...
Pamela Milani (470521), Rachel Marty Pyke (15033824), Michael P. Snyder (15033839), Eric Levy (3713023), Dattatreya Mellacheruvu (531667), Sekwon Jang (8899451), Fábio C.P. Navarro (15033827), Mengyao Tan (14933070), Richard Chen (819249), Simo V. Zhang (6103124), Jason Harris (60019), Charles W. Abbott (9402235), Gabor Bartha (3549785), Lee D. McDaniel (4033088), Rose Santiago (15033830), Sean M. Boyle (15033821), Zeid M. Rusan (15033833), Rena McClory (15033836)   +17 more
core   +2 more sources

Redefining innate natural antibodies as important contributors to anti-tumor immunity

eLife, 2021
Myeloid, T, and NK cells are key players in the elimination phase of cancer immunoediting, also referred to as cancer immunosurveillance. However, the role of B cells and NAbs, which are present prior to the encounter with cognate antigens, has been ...
Kavita Rawat, Anita Tewari, Madeline J Morrisson, Tor D Wager, Claudia V Jakubzick   +4 more
doaj   +1 more source

Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model [PDF]

Gastroenterology, 2021
DNA mismatch repair deficiency drives microsatellite instability (MSI). Cells with MSI accumulate numerous frameshift mutations. Frameshift mutations affecting cancer-related genes may promote tumorigenesis and, therefore, are shared among independently arising MSI tumors.
Johannes Gebert, Ozkan Gelincik, Mine Oezcan-Wahlbrink, Jason D. Marshall, Alejandro Hernandez-Sanchez, Katharina Urban, Mark Long, Eduardo Cortes, Elena Tosti, Eva-Maria Katzenmaier, Yurong Song, Ali Elsaadi, Nan Deng, Eduardo Vilar, Vera Fuchs, Nina Nelius, Yan P. Yuan, Aysel Ahadova, Shizuko Sei, Robert H. Shoemaker, Asad Umar, Lei Wei, Song Liu, Peer Bork, Winfried Edelmann, Magnus von Knebel Doeberitz, Steven M. Lipkin, Matthias Kloor   +27 more
openaire   +4 more sources

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

OncoImmunology, 2020
Tumors acquire numerous mutations during development and progression. When translated into proteins, these mutations give rise to neoantigens that can be recognized by T cells and generate antibodies, representing an exciting direction of cancer ...
Yingxue Ren, Yesesri Cherukuri, Daniel P. Wickland, Vivekananda Sarangi, Shulan Tian, Jodi M. Carter, Aaron S. Mansfield, Matthew S. Block, Mark E. Sherman, Keith L. Knutson, Yi Lin, Yan W. Asmann   +11 more
doaj   +1 more source

Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

BMC Cancer, 2018
Background Patients with highly mutated tumors, such as melanoma or smoking-related lung cancer, have higher rates of response to immune checkpoint blockade therapy, perhaps due to increased neoantigen expression.
Timothy O’Donnell, Elizabeth L. Christie, Arun Ahuja, Jacqueline Buros, B. Arman Aksoy, David D. L. Bowtell, Alexandra Snyder, Jeff Hammerbacher   +7 more
doaj   +1 more source

Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes [PDF]

Scientific Reports, 2019
AbstractLymph node metastasis is of major prognostic significance for breast cancer. Lymph node metastasis arises at a very early stage in some patients. Using the data downloaded from the TCGA database, we studied the differences between primary tumors with and without lymph node metastasis at the multi-omics level using bioinformatics approaches. Our
Zhigang Wang, Wei Liu, Chong Chen, Xiaolin Yang, Yunping Luo, Bailin Zhang   +5 more
openaire   +2 more sources

Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

The Journal of Clinical Investigation, 2023
Carcinogen exposure is strongly associated with enhanced cancer immunogenicity. Increased tumor mutational burden and resulting neoantigen generation have been proposed to link carcinogen exposure and cancer immunogenicity.
Mei Huang, Yun Xia, Kaiwen Li, Feng Shao, Zhaoyi Feng, Tiancheng Li, Marjan Azin, Shadmehr Demehri   +7 more
doaj   +1 more source